Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,727 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,614 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00551369 | Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery | completed | Phase 2 | 33 | Radiation Therapy Oncology GroupNETWORK | 1 | Apr 30, 2019 | clinicaltrials |
| NCT01253369 | Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 23, 2019 | clinicaltrials |
| NCT02176369 | Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial(ONC-MANILA12) | completed | Phase 2 | 120 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 22, 2019 | clinicaltrials |
| NCT01173523 | Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 | 25 | David M. Jackman, MDOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT00780234 | Pioglitazone for Lung Cancer Chemoprevention | completed | Phase 2 | 92 | VA Office of Research and DevelopmentFED | 1 | Apr 11, 2019 | clinicaltrials |
| NCT02054052 | Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer | completed | Phase 2 | 22 | Haihong Yang, MD, Pricipal investigatorOTHER | 1 | Mar 29, 2019 | clinicaltrials |
| NCT00541099 | Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 11 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 27, 2019 | clinicaltrials |
| NCT01685138 | LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer | completed | Phase 2 | 124 | Novartis PharmaceuticalsINDUSTRY | 18 | Mar 26, 2019 | clinicaltrials |
| NCT00614822 | Carboplatin, Bevacizumab and Pemetrexed in Advanced Non Small Cell Lung Cancer(H3E-US-X072) | completed | Phase 2 | 50 | Christiana Care Health ServicesOTHER | 0 | Mar 20, 2019 | clinicaltrials |
| NCT01949701 | Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*02 Disease Controlled Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 6 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01950156 | Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 Disease Controlled Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 6 | Shiga UniversityOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT02340208 | A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 | completed | Phase 1 / Phase 2 | 76 | Helix BioPharma CorporationINDUSTRY | 1 | Mar 14, 2019 | clinicaltrials |
| NCT01487265 | Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib | completed | Phase 2 | 37 | SCRI Development Innovations, LLCOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT00100854 | Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 108 | Translational Oncology Research InternationalOTHER | 1 | Mar 5, 2019 | clinicaltrials |
| NCT00459342 | Dasatinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01786187 | The Symptom Experience Study in Persons With Non-Small Cell Lung Cancer(SES) | completed | Phase 1 / Phase 2 | 87 | Michigan State UniversityOTHER | 1 | Feb 25, 2019 | clinicaltrials |
| NCT02040870 | LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib | completed | Phase 1 / Phase 2 | 103 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 20, 2019 | clinicaltrials |
| NCT00495170 | Concurrent Proton and Chemotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 84 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 6, 2019 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT03239171 | Bioinformation Therapy for Lung Cancer | completed | Phase 2 / Phase 3 | 120 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Jan 25, 2019 | clinicaltrials |
| NCT00281970 | Docetaxel and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Has Been Completely Removed By Surgery | completed | Phase 2 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 17, 2019 | clinicaltrials |
| NCT00087438 | Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer | completed | Phase 2 | 59 | Radiation Therapy Oncology GroupNETWORK | 1 | Jan 16, 2019 | clinicaltrials |
| NCT02155465 | Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib | completed | Phase 1 / Phase 2 | 22 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 16, 2019 | clinicaltrials |
| NCT01415011 | Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients(TIMELY) | completed | Phase 2 | 39 | University College, LondonOTHER | 1 | Jan 15, 2019 | clinicaltrials |
| NCT00495040 | Proton Radiotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 14, 2019 | clinicaltrials |
| NCT02976883 | [18F]HX4 PET/CT Imaging for Detection of Hypoxia(OXYPET) | completed | Phase 2 | 8 | Nottingham University Hospitals NHS TrustOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT00918203 | A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 137 | Eli Lilly and CompanyINDUSTRY | 2 | Jan 10, 2019 | clinicaltrials |
| NCT01465802 | Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO(ARCHER 1042) | completed | Phase 2 | 236 | PfizerINDUSTRY | 2 | Jan 9, 2019 | clinicaltrials |
| NCT00125359 | Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer | completed | Phase 2 | 42 | Konstantin DragnevOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT01846416 | A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR] | completed | Phase 2 | 138 | Genentech, Inc.INDUSTRY | 5 | Jan 8, 2019 | clinicaltrials |
| NCT02403271 | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 124 | Pharmacyclics LLC.INDUSTRY | 1 | Jan 3, 2019 | clinicaltrials |
| NCT02599194 | 18F-FSPG PET/CT for Cancer Patients on Therapy | completed | Phase 2 | 7 | Andrei IagaruOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT00385996 | Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer | completed | Phase 2 | 22 | Weill Medical College of Cornell UniversityOTHER | 1 | Dec 28, 2018 | clinicaltrials |
| NCT01497873 | A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer | completed | Phase 2 | 164 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Dec 27, 2018 | clinicaltrials |
| NCT02038647 | Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC) | completed | Phase 2 | 178 | Millennium Pharmaceuticals, Inc.INDUSTRY | 10 | Dec 27, 2018 | clinicaltrials |
| NCT02149576 | Does Intense Regimented Surveillance Improve the Rates of Therapeutic Re-Intervention After Lung Cancer Surgery(Intense-CT) | completed | Phase 2 | 313 | McMaster UniversityOTHER | 1 | Dec 20, 2018 | clinicaltrials |
| NCT01055197 | Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 97 | Radiation Therapy Oncology GroupNETWORK | 3 | Dec 12, 2018 | clinicaltrials |
| NCT00567359 | Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR | completed | Phase 2 | 100 | Massachusetts General HospitalOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT02289456 | Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2(AboundPS2) | completed | Phase 2 | 40 | CelgeneINDUSTRY | 1 | Dec 7, 2018 | clinicaltrials |
| NCT00287989 | Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 86 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 6, 2018 | clinicaltrials |
| NCT00390429 | Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors | completed | Phase 1 / Phase 2 | 81 | University of California, DavisOTHER | 1 | Dec 6, 2018 | clinicaltrials |
| NCT02655913 | Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer(VCONSCLC) | completed | Phase 1 / Phase 2 | 97 | Clifford Hospital, Guangzhou, ChinaOTHER | 1 | Nov 30, 2018 | clinicaltrials |
| NCT02200081 | Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC(IMPULSE) | completed | Phase 2 | 103 | Mologen AGINDUSTRY | 4 | Nov 15, 2018 | clinicaltrials |
| NCT00043823 | Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer | completed | Phase 1 / Phase 2 | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT01801111 | A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment | completed | Phase 1 / Phase 2 | 138 | Hoffmann-La RocheINDUSTRY | 16 | Nov 2, 2018 | clinicaltrials |
| NCT00389805 | Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors | completed | Phase 1 / Phase 2 | 27 | University of California, DavisOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT01260181 | A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations | completed | Phase 2 | 30 | Hoffmann-La RocheINDUSTRY | 1 | Oct 31, 2018 | clinicaltrials |
| NCT01829217 | Sunitinib in Never-Smokers With Lung Adenocarcinoma | completed | Phase 2 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00016367 | Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 26, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Apr 30, 2019source: clinicaltrials